Unknown

Dataset Information

0

[A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation ?Treated with Anlotinib].


ABSTRACT: In recent years, the number of advanced non-small cell lung cancer (NSCLC) patients has gradually increased, and the treatment methods have also been significantly increased. However, there are no standard treatment plans at home and abroad for third-line and above patients who are refractory to targeted therapy epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) or chemotherapy. The clinical treatment effect is also not satisfactory. Anlotinib is a novel TKI targeting the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit. ALTER0303 trail, phase III study has demonstrated that Anlotinib significantly prolonged overall survival (OS) and progression-free survival (PFS) in advanced NSCLC patients as 3rd line treatment.Here we report a case of advanced lung adenocarcinoma harboring KRAS mutation treated with Anlotinib.?.

PROVIDER: S-EPMC5999919 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC6372914 | BioStudies
2020-01-01 | S-EPMC7163095 | BioStudies
2020-01-01 | S-EPMC7476093 | BioStudies
2019-01-01 | S-EPMC6774020 | BioStudies
2019-01-01 | S-EPMC6835105 | BioStudies
2019-01-01 | S-EPMC6749025 | BioStudies
2020-01-01 | S-EPMC7377159 | BioStudies
2018-11-30 | E-MTAB-5997 | BioStudies
2019-01-01 | S-EPMC6585030 | BioStudies
2018-11-30 | E-MTAB-5997 | ArrayExpress